Power3 Medical Products Inc. CEO Interview: Helen R. Park

• On 3:11 pm EDT, Tuesday September 15, 2009

67 WALL STREET, New York - September 15, 2009 - The Wall Street Transcript has just published its Medical Research Services report offering a timely review of the sector to serious investors and industry executives. This 23 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Medical Device Research Services - Pharmaceutical Research Services - Diagnostics - Life Science Research Supplies - Biology R & D - Lab Services Business Model - International Economic Exposure - Effect of Recession on Sector Stocks - Top Stock Winners and Losers in Medical Research Services - Top Stock Winners and Losers in Medical Diagnostics

Companies include: Arrowhead Research (ARWR); Cleveland BioLabs (CBLI); IR BioSciences Holdings (IRBS); Power3 Medical Products (PWRM); Illumina (ILMN); Luminex (LMNX); Waters (WAT); Life Technologies (LIFE); QIAGEN (QGEN); Sangamo BioSciences (SGMO); Beckman Coulter (BEC); Invitrogen (IVGN); Amgen (AMGN); Bristol-Myers (BMY); Eli Lilly & Co. (LLY); Myriad Genetics (MYGN); Genomic Health (GHDX); Targeted Genetics (TGEN); Dow Chemical (DOW); Sigma-Aldrich (SIAL); MDS (MDZ); Danaher (DHR); Cepheid (CPHD); Inverness Medical Innovations (IMA); Quidel (QDEL); Meridian Bioscience (VIVO); Gen-Probe (GPRO); Sequenom (SQNM); Genoptix (GXDX); Response Genetics (RGDX); Affymetrix (AFFX); Monogram Bioscience (MGRN); LabCorp (LH)

In the following brief excerpt from the 23 page report, Helen R. Park discusses the outlook for the sector and for investors.

TWST: Would you give a brief history of your company and what your focus is now?

Ms. Park: Power3 had a change in direction in 2004 when it purchased the assets of Advanced Bio/Chem, Inc. This technology became the focus of the company. We have discovered protein biomarkers in blood serum for several diseases, including Alzheimer's, Parkinson's and breast cancer. We are taking them to commercialization as blood tests. To that end, Power3 Medical Products is engaged in clinical validation trials for Alzheimer's and Parkinson's with a commercial partner and collaborators from Greece and the US.

TWST: Where are you in the process of transitioning from an R&D company to one that commercializes its products and technology?

Ms. Park: We are midway through the clinical validation trials for Alzheimer's and Parkinson's disease.

TWST: What are your priorities for the next four to eight quarters as you move forward?

Ms. Park: Our priorities are to move forward with our clinical validation trials for the Alzheimer's and Parkinson's disease, restart breast cancer and commercialize these tests.

TWST: Can you talk a little bit about these products for Alzheimer's and Parkinson's?

Ms. Park: These are diagnostic tests that use serum protein biomarkers that can discriminate between age-matched normal controls, Alzheimer's disease patients and Alzheimer's disease-like patients. The biomarkers for Parkinson's disease can discriminate between age-matcheded normal controls, Parkinson's disease patients and Parkinson's disease-like patients. Our discovery and initial development work has been published in several articles. The first report of our clinical validation trial work will be submitted for publication this month. It demonstrates the potential of early detection.

TWST: How are your products different from products that are currently on the market?

Ms. Park: The tests for Alzheimer's and Parkinson's are using primarily symptoms. Then the specialists add extensive testing, imaging, spinal tap, etc. This is very time-consuming and expensive. Some companies are using genetic tests and others general disease reactive biomarkers.

TWST: You also have a product in early detection blood serum for breast cancer, BC-SeraPro. Where is that in terms of FDA approval?

Ms. Park: None of our products have proceeded to FDA approval. Because of the downturn in the economy and the fact that we had to reduce the size of the company for space and personnel, we have put all of our resources into neurodegenerative disease. The breast cancer test at this time is halted in clinical validation trial Phase I. We are pursuing partners to move ahead.

TWST: What do you consider your competitive advantage?

Ms. Park: Our competitive advantage is that we can distinguish between the controls and the disease by using more specific biomarkers, which actually indicate the disease mechanisms and the fact that we are looking at biomarkers that are directly related to what the neurologists would want to see as far as what the disease is doing to the patient. In other words, you can have a genetic test for a disease and it might say, "Oh we think you might have a higher risk of getting this," but we can look directly at the diseased cell proteins being released into the serum, and that's what we are capturing in our neurodegenerative diagnostic tests. We are seeing these in the blood.

TWST: What are two or three reasons for investors to look closely at your company right now?

Ms. Park: Number one, we have tests and biomarkers that are in the process of validation in clinical trials. Number two, we have a strong background not only in the technology, but we have improved it for 10 years with our proprietary procedures. And third, we have experience in the commercialization of diagnostic tests.

TWST: Do you have an R&D team now?

Ms. Park: Yes, we have the laboratory up and running.

TWST: What $300 million company was your CFO previously working for?

Ms. Park: Critical Care Systems, Inc.

TWST: How big is your current team right now?

Ms. Park: We have one full-time employee and the others are on contract. With part-time and full-time people there are nine people. I'm being very careful with the money.

TWST: Would you say you are capitalized enough at the moment to keep going?

Ms. Park: No.

TWST: How much capital would you need to continue to float as a public company?

Ms. Park: We have projected for this year about $800,000 to move at the rate needed to keep ahead of our competitors.

TWST: $800,000 that you have currently or have a shortfall of?

Ms. Park: Shortfall. We have been able to keep moving but not at the pace we want.

TWST: Is there anything else that you would like to add?

Ms. Park: Well, I think that we do have a tremendous potential, otherwise I would not have accepted the position in September of 2008 and continued because I still had consulting agreements with other companies when I came in. So this is a 24-7 job and my husband has Parkinson's disease and I really need to be spending more time helping him. So I would not be spending my time doing this unless I had my heart and soul in this technology and in the biomarkers and diagnostic tests. This is a diagnostic test using blood for Alzheimer's, Parkinson's and ALS. And we want to get started again on the breast cancer test.

TWST: Thank you. (MR)

Helen R. Park CEO Power3 Medical Products Inc. 3400 Research Forest Drive Suite B2-3 The Woodlands, TX 77381 (281) 466-1600 (281) 466-1481 - FAX www.power3medical.com e-mail: hpark@power3medical.com

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 23 page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673

Buzz up!